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Abstract  
CYP3A4 and CYP4A5 share specificity for a wide range of xenobiotics with the CYP3 
subfamily collectively involved in the biotransformation of approximately 30% of all drugs. 
CYP3A4/5 mRNA transcripts have been reported in the skin yet knowledge of their protein 
expression and function is lacking. In this study, we observed gene and protein expression of 
CYP3A4/5 in both human skin and tissue-engineered skin equivalents (TESE), and enzyme 
activity was detected using the model substrate benzyl-O-methyl-cyanocoumarin. Mass 
spectrometric analysis of TESE lysates following testosterone application revealed a time-
dependent increase in metabolite production, confirming the functional expression of these 
enzymes in skin.  
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1  Background 
Cytochrome P450 (CYP450) enzymes are a superfamily of hemoproteins that metabolize a 
multitude of endogenous and xenobiotic molecules and are essential to maintain 
homeostasis.
(1, 2)
 As the most highly expressed xenobiotic enzymes in the liver, they are 
responsible for the majority of phase I reactions, metabolizing between 70-80% of all 
drugs.
(3, 4)
 The CYP3 subfamily of the CYP450 enzymes comprising of CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43  are, collectively involved in the metabolism of over a third of these 
drugs.
(4)
 CYP3A4, the most abundantly expressed isoform in the liver,
(5)
 has a large active 
site that enables its interaction with a wide range of structurally diverse compounds and 
permits metabolism of such molecules and drugs as hormones (testosterone, estrogen), 
anti-cancer drugs (paclitaxel, tamoxifen), and anti-fungal agents (ketoconazole) amongst 
others.
(4, 6)
 CYP3A5 shares 85% amino acid sequence homology with CYP3A4 and displays 
similar substrate specificity.
(7)
 Gene expression of CYP3A4 and CYP3A5 has been detected in 
skin and tissue engineered skin equivalents (TESE) by genomic analysis in some studies
(8, 9, S1, 
S2)
 but not others
(S3)
 and, to date, protein expression has ot been detected.
(S4, S5)
 Given the 
use of skin as a drug delivery route, it is extremely important to determine functional 
expression of CYP3A4/5. Moreover, the increasing use of TESE as an alternative to animal 
testing for drug irritation and sensitivity assays has led to their proposed use in drug-
induced toxicity assays. However, data on functional xenobiotic enzyme activity in these 
models is lacking and urgently required.  
2 QUESTIONS ADDRESSED 
The relative gene and protein expression of CYP3A4 and CYP3A5 in human skin in 
comparison to liver remains unclear. It is also unknown if the expression is localized to the 
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dermis or epidermis and whether the enzymes are functionally active and are able to 
metabolise clinically relevant molecules. 
3 EXPERIMENTAL DESIGN 
See e-supporting information. 
4   RESULTS 
Gene expression levels of CYP3A4 and CYP3A5 were in much greater abundance in the liver 
than skin with expression being several hundred-fold greater for CYP3A4 and 9-fold for 
CYP3A5 respectively (Figure 1A-B). In human liver, gene expression of CYP3A4 was 
significantly greater (p<0.001) than for CYP3A5, whereas, in skin, gene expression of CYP3A5 
was significantly greater (p<0.001) than that of CYP3A4 (Figure 1A-B). Immunoblot analysis 
revealed that both enzymes were also expressed at markedly lower levels in skin compared 
to liver (Figure. 1C-D), confirming the qPCR data. An immuno-positive band corresponding 
to CYP3A5 was not detected in skin at exposure times that were saturating for liver samples, 
however, when probed in isolation, CYP3A5 was detected when the exposure time was 
extended to increase assay sensitivity (Figure 1E). mRNA transcripts for CYP3A4 and CYP3A5 
were detected in TESE. Gene expression levels for CYP3A4 were very low and several 
hundred-fold lower than for CYP3A5, and similar to native skin, TESE expressed significantly 
more mRNA transcripts for CYP3A5 than CYP3A4 (p<0.001) (Figure 1F), and significantly 
more CYP3A4 (p<0.05) and CYP3A5 (p<0.01) was expressed in the epidermis compared to 
the dermis (Figure 1G-H).  Immunohistochemical analysis showed that CYP3A4 was equally 
distributed throughout the epidermis although absent in the cornified layers of both skin 
and TESE (Figure S1A-B). CYP3A4 staining was also observed in the majority of stromal 
fibroblasts and was prominent in the endothelium lining the blood vessels within the 
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connective tissue of native skin (Figure S1A). In contrast, staining was not observed in the 
fibroblasts populating the collagen hydrogel in the TESE (Figure S1B), supporting the qPCR 
data that showed very low mRNA expression in the TSE dermis. In native skin, expression of 
CYP3A5 was largely restricted to the stratum basale (Figure S2C) whereas expression in TESE 
models was extremely weak throughout the entire epithelium (Figure S1D). The discordant 
in immunostaining and qPCR data is likely due to low antibody affinity for CYP3A5. Both 
native skin and TESE revealed no staining in the dermis, suggesting that dermal fibroblasts 
do not express CYP3A5.  
Liver extracts exhibited a maximal reaction velocity (Vmax) of 6694 µmol/min/mg whilst 
native human skin extracts exhibited a lower Vmax of 3215 µmol/min/mg. The Vmax of TESE 
was approximately half that of native skin (1788 µmol/min/mg). Assuming that the enzyme 
catalytic rate (Kcat) for CYP3A for this substrate is the same in liver, skin and TESE, we can 
use these Vmax estimates to calculate the relative tissue/extract enzyme expressions: 
namely, skin:liver=0.48:1; TESE:liver=0.267:1; TESE:skin=0.556:1 (Figure 2A-C). 
Testosterone was applied to the stratum corneum or to the culture medium of TESE for 8 
and 24 hours to mimic topical or systemic delivery. TESE models were separated into 
epidermal and dermal components and extracts of these along with the conditioned 
medium were analysed by mass spectrometry for presence of the CYP3A-generated 
metabolite, 6β-OH-testosterone. When testosterone was applied topically, 6β-OH-
testosterone was detected in the epidermis, dermis and in the culture medium at both 8 
and 24 hours. At 8 hours 6β-OH-testosterone levels were similar in the epidermis, dermis 
and medium whereas after 24 hours the levels of 6β-OH-testosterone found in the 
epidermis were markedly lower, levels in the dermis were similar, whereas levels in the 
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medium had increased five-fold compared to levels at 8 h (p<0.001)(Figure 2D). A markedly 
different pattern of metabolite production was observed when testosterone was added to 
mimic systemic delivery. In these models, the presence of 6β-OH-testosterone was not 
detected in the epidermal or dermal compartments at 8 or 24 hours, whereas after 8 hours, 
6β-OH-testosterone was detected in the culture medium and these levels were significantly 
increased after 24 hours (p<0.001) (Figure 2E).  
5 CONCLUSIONS 
In this study we show both gene and protein expression of predominantly CYP3A5 but also 
CYP3A4 in native skin and TESE. These data have important clinical implications for dermal 
drug delivery of existing or new compounds, in particular those with structural components 
that are likely to be metabolised by CYP3A4/5. They also show that, although expressed at 
lower levels than skin, TESE are able to replicate the kinetics of skin metabolism of topically 
and systemically delivered drugs. 
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10 LEGENDS FOR ILLUSTRATIONS 
Figure 1. Comparison of gene and protein expression levels between human liver, skin and 
TESE for CYP3A4 and CYP3A5. cDNA from human liver and skin was subjected to qPCR 
analysis for CYP3A4 (blue) and CYP3A5 (red) and gene expression relative to GAPDH 
determined for (A) liver and (B) skin. Protein expression in liver and skin was resolved by 
immunoblotting for (C) CYP3A4 and (D) CYP3A5. (E) CYP3A5 expression in skin following 
prolonged exposure during infrared detection of immuno-positive bands; β-actin was used 
as a loading control and immunoblots are representative of 3 independent experiments. (F) 
Relative gene expression of CYP3A4 (blue) and CYP3A5 (red) in whole EpiDerm-FT400™ TESE 
by qPCR analysis. RNA from the epidermis and dermis of EpiDerm-FT400™ TESE was 
isolated, reverse transcribed and subjected to qPCR analysis for (G) CYP3A4 and (H) CYP3A5. 
Data are relative expression to GAPDH. Data are mean ± SD for n=3 independent 
experiments and 3 technical repeats per experiment. * P<0.05, ** P<0.01, ***p<0.001 by 
ANOVA. 
Figure 2. Functional activity of CYP3A in liver, skin and TESE and testosterone metabolism 
by TESE. Protein extracts were generated from human liver, skin and EpiDerm-FT400™ TESE 
and subjected to kinetic enzyme analysis using increasing concentrations of the model 
substrate benzyl-O-methyl-cyanocoumarin (BOMCC). A Nelder-Mead algorithm was used to 
fit the enzyme activity data and all data sets were fit with the assumption that Km (the 
binding affinity for the substrate at half the maximum velocity) was the same in each assay 
(Km = 10 μM). Maximum velocity (Vmax) was calculated as specific metabolic activity of 
CYP3A in μmol/min/mg.  Data are from three independent experiments performed in 
triplicate. Goodness of fit R
2
 values are: (A) 0.8855, (B) 0.9779 and (C) 0.9962.  Testosterone 
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was added either to (C) the surface of the epidermis to mimic topical drug deliver or (D) 
added to the medium that bathes the dermis to mimic systemic drug delivery. The 
production of the specific testosterone metabolite 6β-OH-testosterone was measured by 
mass spectrometry in epidermal and dermal extracts as well as the tissue culture medium 
after 8 and 24 h. Data are from 2 independent experiments and 3 technical repeats per 
experiment. 
Supplementary Figure 1. Spatial localisation of metabolising enzyme expression in native 
skin and TESE. Formalin-fixed, paraffin-embedded sections of native human skin and 
EpiDerm-FT400™ TESE were analysed by immunohistochemistry to determine the spatial 
expression of CYP3A4 (A & B) and CYP3A5 (C & D). IgG was used as a control (E & F). Scale 
bar =100 µm. Images are representative of 3 independent experiments from 3 different 
tissues.  
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Figure 1. Comparison of gene and protein expression levels between human liver, skin and TESE for CYP3A4 
and CYP3A5. cDNA from human liver and skin was subjected to qPCR analysis for CYP3A4 (blue) and 
CYP3A5 (red) and gene expression relative to GAPDH determined for (A) liver and (B) skin. Protein 
expression in liver and skin was resolved by immunoblotting for (C) CYP3A4 and (D) CYP3A5. (E) CYP3A5 
expression in skin following prolonged exposure during infrared detection of immuno-positive bands; β-actin 
was used as a loading control and immunoblots are representative of 3 independent experiments. (F) 
Relative gene expression of CYP3A4 (blue) and CYP3A5 (red) in whole EpiDerm-FT400™ TESE by qPCR 
analysis. RNA from the epidermis and dermis of EpiDerm-FT400™ TESE was isolated, reverse transcribed 
and subjected to qPCR analysis for (G) CYP3A4 and (H) CYP3A5. Data are relative expression to GAPDH. 
Data are mean ± SD for n=3 independent experiments and 3 technical repeats per experiment. * P<0.05, 
** P<0.01, ***p<0.001 by ANOVA.  
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Figure 2. Functional activity of CYP3A in liver, skin and TESE and testosterone metabolism by TESE. Protein 
extracts were generated from human liver, skin and EpiDerm-FT400™ TESE and subjected to kinetic enzyme 
analysis using increasing concentrations of the model substrate benzyl-O-methyl-cyanocoumarin (BOMCC). 
A Nelder-Mead algorithm was used to fit the enzyme activity data and all data sets were fit with the 
assumption that Km (the binding affinity for the substrate at half the maximum velocity) was the same in 
each assay (Km = 10 µM). Maximum velocity (Vmax) was calculated as specific metabolic activity of CYP3A 
in µmol/min/mg.  Data are from three independent experiments performed in triplicate. Goodness of fit R2 
values are: (A) 0.8855, (B) 0.9779 and (C) 0.9962.  Testosterone was added either to (C) the surface of the 
epidermis to mimic topical drug deliver or (D) added to the medium that bathes the dermis to mimic 
systemic drug delivery. The production of the specific testosterone metabolite 6β-OH-testosterone was 
measured by mass spectrometry in epidermal and dermal extracts as well as the tissue culture medium 
after 8 and 24 h. Data are from 2 independent experiments and 3 technical repeats per experiment.  
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Experimental design 
2.1 Tissue engineered skin equivalents (TESE) 
EpiDermFT-400™ TESE comprising of a stratified squamous epithelium composed of 
differentiating skin keratinocytes cultured on top of a dermal fibroblast-populated collagen 
hydrogel were purchased from MatTek Corporation (Ashland, MA, USA). Upon receipt 
EpiDermFT-400™ TESE were transferred to 6 well plates and incubated overnight at 37°C, 
5% CO2 in a modified flavin- and adenine- enriched medium consisting of: DMEM and Ham’s 
F12 medium in a 3:1 (v/v) ratio supplemented with 10% (v/v) fetal calf serum (FCS), 0.1 mM 
cholera toxin, 10 ng/ml epidermal growth factor, 0.18 mM adenine, 5 µg/ml insulin, 5 µg/ml 
transferrin, 2 mM glutamine, 0.2 mM triiodothyronine, 0.625 mg/ml amphotericin B, 100 
IU/ml penicillin and 100 mg/ml streptomycin (all Sigma, Poole, UK).
(S6)
 
 
2.2  RNA and protein extraction 
Whole TESE, or separated epithelial and dermal layers from EpiDermFT-400™ TESE were 
homogenized to ensure complete lysis and total RNA extracted using the RNAeasy mini kit 
(Qiagen, Hilden, Germany). For protein lysis, all samples were snap frozen with liquid 
nitrogen, homogenized with a pestle and mortar, transferred to lysis buffer (50 mM Tris, 
150 mM NaCl, 1% Triton-X-100, pH 7.6) and aspirated through a 25-gauge needle before 
incubation on ice for 20 minutes. Samples were then centrifuged at 15,000 x g for 20 
minutes with the resulting supernatants removed and stored at -80°C. Protein levels were 
determined using a bicinchoninic acid protein assay (ThermoFisher Scientific, MA, USA). 
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2.3  Quantitative real-time PCR analysis 
One µg of human liver total RNA (Amsbio, Abingdon, UK), human skin total RNA (Amsbio, 
Abingdon, UK) or EpiDermFT-400™ TESE total RNA was reversed transcribed to cDNA using 
High Capacity Reverse Transcription kit (Applied Biosystems, CA, USA) according to the 
manufacturer’s instructions. Quantitative real-time polymerase chain reaction (PCR) was 
performed in a 10 μl reaction volume using 1 μl of cDNA, along with Taqman MGB human 
FAM-labelled probes CYP3A4 (Hs00604506_m1), CYP3A5 (Hs01070905_m1) and GAPDH 
(Hs02758991_g1) (ThermoFisher) and Taqman Mastermix, and the reaction carried out in a 
7900HT Fast Real-Time PCR System (Applied Biosystems, CA, USA). Critical threshold (ct) and 
ΔCt values were calculated for each sample and relative expression of target genes, 
normalized to the abundance of the reference control transcript (GAPDH) calculated. For 
certain analysis, the relative fold change in gene expression was calculated using the 
formula 2
−ΔΔCt
. 
 
2.4  Immunoblotting 
Thirty μg of human liver tissue lysate (Abcam, Cambridge, UK) or human skin tissue lysate 
(Abcam) were separated by SDS-PAGE (4-12%) and transferred to nitrocellulose membranes 
(Bio-Rad, Watford, UK). Membranes were blocked for 1 hour in 5% TBST (5% milk powder, 
Tris-buffered Saline, 0.1% Tween-20) at room temperature. Membranes were incubated at 
4°C overnight with primary antiserum directed against CYP3A4 (1:200, EPR6202, Abcam), 
CYP3A5 (1:500, EPR4396, Abcam) or β-actin (1:3000, Abcam) diluted in 5% TBST. After 
washing in TBST, membranes were incubated for 1 hour in 5% TBST with either IRDye 
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800CW donkey anti-rabbit (1:10,000, 926-32213, LI-COR Biosciences) or IRDye 680RD 
donkey anti-goat (1:10,000, 926-68074, LI-COR Biosciences) antiserum. Membranes were 
washed an additional three times with TBST prior to development using LI-COR Odyssey 
system (LI-COR Biosciences). 
 
2.5  Immunohistochemistry 
Formalin-fixed, paraffin-embedded native skin obtained with informed, written consent 
from patients undergoing maxillofacial surgery (ethical approval 09/H1308/66) or 
EpiDermFT-400™ TESE were sectioned (5 µm) and mounted on adhesive glass slides (Leica 
Biosystems, Wetzlar, Germany). Antigen retrieval was performed using citrate buffer (10 
mM sodium citrate, 0.05 % Tween-20, pH 6.0, 20 min, 95°C) or Tris buffer (10 mM Tris Base, 
0.05% Tween-20, pH 10) in a 2100 Antigen Retriever (Aptum Biologics Ltd, Hampshire, UK). 
Sections were blocked for 30 minutes at room temperature using serum-free protein block 
(Dako-Agilent Technologies, CA, USA) for 20 minutes and then incubated for 1 hour with 
primary antibody directed to CYP3A4 (1:250, ab3572, Abcam), CYP3A5 (1:250, ab108624, 
Abcam); IgG was used as a non-specific control. Following washing with PBS, sections were 
incubated with a biotinylated secondary antibody for one hour, followed by a 30 minute 
incubation with an avidin-biotin complex kit (Vectastatin Elite ABC kit, Vector Laboratories, 
Peterborough, UK) and antigens visualized using 30-diaminobenzidine tetrahydrochloride 
(DAB) (Vector Labs), according to the manufacturer’s instructions. Nuclei were 
counterstained with haematoxylin, and sections then dehydrated and mounted in DPX. 
Images were taken using an Olympus BX51 microscope and Colour view IIIu camera with 
associated Cell^D software (Olympus Soft Imaging Solutions GmbH, Münster, Germany).  
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2.6 CYP3A kinetic assay  
The commercially available Vivid® CYP450 Blue Screening Kit (ThermoFisher Scientific, MA, 
USA) was modified to assess functional activity following CYP3A biotransformation of 
benzyl-O-methyl-cyanocoumarin (BOMCC). Forty µl of liver, skin or EpiDermFT-400™ cell 
lysate and 50 µl of master mix (49 µl of 1 x reaction buffer, 1 µl of regeneration system) was 
added to each well of a 96-well plate and the plate was incubated at room temperature for 
10 minutes. 10 µl of substrate mix was added to each well (1 x reaction buffer, Vivid® 
NADP+, and desired concentration of Vivid® BOMCC substrate) and readings taken at 
excitation wavelength 415 nm and emission wavelength 460 nm at 10-minute intervals for a 
total of 120 minutes using a Tecan spectrophotometer. Concentrations were interpolated 
from a standard curve generated using standards provided with kit. A Nelder-Mead fitting 
algorithm within Matlab (MathsWorks Inc.) was used to fit the enzyme activity data to 
Michaelis-Menten kinetic curves (of the form, v0=Vmax [BOMCC]/(Km+[BOMCC]), where Km 
(mM) is the Michaelis-Menten enzyme-substrate affinity constant and Vmax = Kcat[CYP3] 
(μmol/min/mg) is the maximum enzyme activity rate, where Kcat (1/min) is the turnover 
catalytic rate and [CYP3] (μmol/mg) is the total CYP3 expression and [BOMCC] is the 
concentration of substrate (μM). Coefficient of determination (R
2
) is used as a determinant 
of goodness of fit in each case. All data sets were independently fit with the assumption that 
the binding affinity Km value was the same for each assay (Km for BOMCC = 10 μM (data 
provided by ThermoFisher Scientific) - under the assumption that CYP3:BOMCC interactions 
occurred with the same affinity in each case). Enzyme expression fold changes were 
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obtained by calculating the ratio of Vmax values under the assumption that the turnover 
catalytic rate (Kcat) was also the same in each assay.   
 
2.7  Mass Spectrometry 
EpiDermFT-400™ TESE were transferred to 6-well plates and incubated overnight at 37°C, 
5% CO2 in a modified flavin- and adenine- enriched medium. TESE were treated with 1 mM 
testosterone (Sigma, Poole, UK) in phenol red-free medium for 8 and 24 hours, either to the 
surface of the model (to mimic topical delivery) or within the culture medium (to mimic 
systemic delivery). The epidermal and dermal layers were separated using forceps and each 
placed into 2 ml of phenol red-free medium before being snap frozen and stored in liquid 
nitrogen. Testosterone analysis was carried out as previously described.
(S7)
 In brief, samples 
were analysed using a quadrupole linear ion trap mass spectrometer (AB Sciex 4000 QTrap) 
coupled to a Dionex Ultimate 3000 HPLC system. 10 μL of each sample was separated using a 
Phenomenex Luna 5 µ C18(2) 100A 100 x 2.00 mm column and a gradient consisting of 0.1 % formic 
acid in water (mobile phase A) and methanol (mobile phase B) with a 200 mL/minute flow rate. The 
column oven and auto-sampler were maintained at 30°C and 4°C respectively. The mass 
spectrometer was operated using the multiple reaction monitoring mode and the analytes detected 
and quantified using the most abundant transitions obtained during direct infusion of commercially 
available LC-MS-MS grade standard. 
 
2.8 Statistical Analysis 
All data presented are from at least 3 independent experiments unless stated otherwise and 
results expressed as mean ± standard deviation (SD). Differences between groups were 
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measured using Student’s t-test calculated in Graphpad Prism v6.0 (GraphPad, La Jolla, CA) 
and statistical significance was assumed if p<0.05. 
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Re: EXD-17-0151.R1  
Dear Prof. Thomas Luger,  
We thank the reviewers for taking the time to consider our revised manuscript "Expression and enzyme 
activity of the Cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue engineered skin 
equivalents” for publication in Experimental Dermatology as a Letter to the Editor.  
 
Our responses are detailed below:  
Reviewer: 1  
 
Suggestions for Authors  
The manuscript has now been revised to the Letter format with much compressed but concise content – 
without the loss of the essential information. The authors have also addressed adequately the earlier 
comments raised by the reviewers. The manuscript is acceptable for publication in its current form.  
 
The authors thank the review for their comments.  
 
Reviewer: 2  
 
Suggestions for Authors  
The authors provided a well reduced form of their manuscript and perfectly responded to the reviewers' 
comments making this manuscript worth for publication. However, if not missed, the authors forgot to 
include a figure legend for figure 3.  
 
We thank reviewer two for their kind comments. We believe what reviewer two is referring to as figure 
three is actually supplementary figure 1. A figure legend was included in the main body of text but was 
not embedded within the figure (TIFF file). I have contacted Ms Moir, Editorial Assistant Experimental 
Dermatology Editorial Office, who states that the figure legend should be included in the main 
document but also to embed the figure legend in the figure TIFF file. This has now been corrected. 
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